Clinical trial
SWITCH Mixtard® 30 NovoLet® to NovoMix® 30 FlexPen®. An Observational Study
NCT01536626 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- SWITCH Mixtard® 30 NovoLet® to NovoMix® 30 FlexPen®. An Observational Study
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Observational
- Overall status
- Completed
- Start date
- June 9, 2006
- Completion date
- April 10, 2007
- Enrollment
- 211 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
diabetes, diabetes mellitus, type 2